

Contents

List of Contributors — XXVII

Shital Gandhi, Dan Farine

1 Introduction — 1

1.1 What Is Obstetric Medicine? — 1

1.2 Why Obstetric Medicine? — 2

Gali Pariente, Gideon Koren

2 Approach to Safe Use of Medications in Pregnancy — 5

2.1 Introduction — 5

2.2 Medication Use in Pregnancy — 5

2.3 Teratogenicity — 6

2.3.1 Timing of Exposure — 6

2.3.2 Teratogenic Mechanisms — 7

2.3.3 Labeling Requirements — 7

2.4 Drug Pharmacokinetics — 8

2.4.1 Pregnancy-Induced Pharmacokinetic (PK) Changes of Drugs — 8

2.4.2 Placental Drug Transfer — 9

2.5 Drug Pharmacodynamics — 9

2.5.1 Maternal Drug Actions — 9

2.5.2 Drugs of Choice — 10

2.6 Therapeutic Drug Actions in the Fetus — 13

2.7 Proven Teratogenic Drugs in Humans — 13

2.7.1 Drugs for Cardiovascular Disorders — 13

2.7.2 Drugs for Neurological Disorders — 14

2.7.3 Drugs of Abuse — 14

2.7.4 Drugs Used for Infection and Inflammation — 14

2.7.5 Drugs for Nausea and Vomiting — 15

2.7.6 Other Drugs — 15

2.8 Drugs in Normal Labor and Delivery — 16

2.8.1 Pharmacologic Management of Pain During Labor and Delivery — 16

2.8.2 Drugs for Management of Labor Protraction or Arrest Disorders — 16

2.9 Conclusion — 18

References — 19

Siobhan Bacon, Ann McNamara

3	Approach to Diagnostic Imaging in Pregnancy — 23
3.1	Introduction — 23
3.2	Fetal Effects of Radiation: Teratogenicity — 23
3.3	Fetal Effects of Radiation: Oncogenesis — 25
3.4	Maternal Effects of Ionizing Radiation — 25
3.5	Specific Modalities: Non-ionizing Radiation — 26
3.5.1	Ultrasound — 26
3.5.2	Magnetic Resonance Imaging (MRI) — 26
3.6	Specific Modalities: Ionizing Radiation — 27
3.6.1	Plain Film — 27
3.6.2	Computed Tomography (CT) — 27
3.7	Nuclear Imaging: Positron Emission Tomography Scanning Scan — 27
3.8	Imaging in Particular Clinical Scenarios — 28
3.8.1	Headache — 28
3.8.2	Non-obstetric Abdominal Pain — 29
3.8.3	Suspected Pulmonary Embolism — 30
3.9	Contrast Agents — 30
3.9.1	Gadolinium — 30
3.9.2	Iodinated Contrast — 31
3.10	How to Reduce Radiation Exposure — 31
3.11	Lactation — 32
	Conclusion — 32
	Glossary — 32
	References — 33

Jennifer Yo, Shital Gandhi

4	Chronic Hypertension — 35
4.1	Introduction — 35
4.2	Definition and Diagnostic Criteria for Hypertensive Disorders in Pregnancy — 35
4.2.1	Gestational Hypertension — 35
4.2.2	Preeclampsia — 36
4.2.3	Chronic Hypertension — 36
4.2.4	Chronic Hypertension with Superimposed Preeclampsia — 37
4.2.5	White Coat Hypertension — 37
4.3	Normal Hemodynamic Changes in Pregnancy — 37
4.4	Comorbid Conditions — 38
4.5	Pregnancy Complications in Women with Chronic Hypertension — 39
4.5.1	Maternal Risks — 39
4.5.2	Fetal Risks — 39

4.6	Patient Evaluation —	39
4.7	Blood Pressure Measurement —	40
4.8	Blood Pressure Target in Pregnancy —	40
4.8.1	Management of Non-severe Hypertension (BP 140–159/90–110 mmHg) —	40
4.8.2	Management of Severe Hypertension (BP $\geq$ 160/110 mmHg) —	42
4.9	Choice of Antihypertensive Agent —	42
4.9.1	Sympathetic Nervous System Inhibition —	43
4.9.2	Beta-Adrenergic Blockers —	43
4.9.3	Calcium Channel Blockers —	44
4.9.4	Direct Vasodilators —	44
4.9.5	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists —	45
4.10	Management of Postpartum Hypertension —	45
	References —	46

Laura Berall, Michelle A. Hladunewich

5	Kidney Disease in Pregnancy —	49
5.1	Introduction —	49
5.2	Renal Physiology in Normal Pregnancy and the Diagnosis of Kidney Disease —	49
5.3	Renal Biopsy in Pregnancy —	51
5.4	Acute Kidney Injury in Pregnancy —	51
5.5	Pregnancy in Women with Chronic Kidney Disease —	56
5.5.1	Prepregnancy Counseling and Optimization —	56
5.5.2	Management of CKD in Pregnancy —	57
5.5.3	Postpartum Care —	58
5.6	Disease-Specific Comments —	59
5.6.1	Lupus Nephritis in Pregnancy —	59
5.6.2	Diabetic Nephropathy in Pregnancy —	59
5.6.3	Hereditary Kidney Disease in Pregnancy —	60
5.7	Pregnancy in End-Stage Kidney Disease —	61
5.7.1	Pregnancy and Renal Transplant Recipients —	61
5.7.2	Pregnancy in Women on Dialysis —	61
5.8	Conclusion —	62
	References —	63

Kelsey McLaughlin, Melanie C. Audette, Sebastian R. Hobson,
John C. Kingdom

6	Preeclampsia —	69
6.1	Introduction —	69
6.2	Preeclampsia Pathogenesis: Stage 1 —	70

- 9.6 Perimortem Caesarian Section Delivery — **125**
- 9.7 Mechanical Support and Intensive Care Management — **126**
- 9.8 Outcomes and Training Perspectives — **127**
- References — **127**

Stephanie C. Lapinsky, Stephen E. Lapinsky

- 10 Critical Care in Pregnancy — 131**
 - 10.1 Introduction — **131**
 - 10.2 Physiologic Changes in Pregnancy — **131**
 - 10.3 Critical Illness in Pregnancy — **133**
 - 10.4 Critical Care Management: ICU Drug Therapy in Pregnancy — **134**
 - 10.4.1 Catecholamines — **134**
 - 10.4.2 Sedation, Analgesia, and Neuromuscular Blockade — **134**
 - 10.5 Ventilatory Support — **135**
 - 10.5.1 Noninvasive Ventilation — **135**
 - 10.5.2 Airway Management — **135**
 - 10.5.3 Mechanical Ventilation — **135**
 - 10.6 Pregnancy-Specific Conditions Requiring ICU Care — **136**
 - 10.6.1 Acute Fatty Liver of Pregnancy — **137**
 - 10.6.2 Amniotic Fluid Embolism — **137**
 - 10.6.3 Obstetric Hemorrhage — **138**
 - 10.6.4 Tocolytic Pulmonary Edema — **139**
 - 10.7 Conditions Not Specific to Pregnancy — **139**
 - 10.7.1 Acute Respiratory Distress Syndrome in Pregnancy — **139**
 - 10.7.2 Thyroid Storm — **139**
 - 10.7.3 Trauma — **140**
 - References — **141**

Dina Refaat, Mohamed Momtaz

- 11 Amniotic Fluid Embolism — 145**
 - 11.1 Introduction — **145**
 - 11.1.1 History — **145**
 - 11.1.2 Definition — **146**
 - 11.1.3 Incidence — **146**
 - 11.2 Risk Factors — **147**
 - 11.3 Pathophysiology — **147**
 - 11.4 Clinical Presentations — **148**
 - 11.5 Diagnosis — **148**
 - 11.6 Differential Diagnosis — **149**
 - 11.6.1 Myocardial Infarction — **149**
 - 11.6.2 Pulmonary Embolism — **149**
 - 11.6.3 Anesthetic Complications — **149**

11.6.4	Air Embolism — 150
11.6.5	Eclampsia — 150
11.6.6	Transfusion Reactions — 150
11.6.7	Anaphylactic Shock — 150
11.7	Management — 150
11.8	Complications — 152
11.8.1	Maternal Complications — 152
11.8.2	Fetal Complications — 153
	References — 154

Sam Schulman, Aleksander Makatsariya

12	Venous Thromboembolism in Pregnancy — 157
12.1	Introduction — 157
12.2	Risk Factors for Venous Thromboembolism — 157
12.2.1	Physiological Changes in Pregnancy — 158
12.2.2	Pathology in Pregnancy — 159
12.2.3	Fetus-Related Risks — 159
12.2.4	Patient-Related Risk Factors — 159
12.3	Diagnosis of VTE in Pregnancy — 161
12.3.1	Deep Vein Thrombosis — 161
12.3.2	Pulmonary Embolism — 162
12.3.3	Clinical Prediction — 162
12.4	Prophylaxis — 163
12.5	Treatment — 166
12.5.1	Initiation of Treatment — 166
12.5.2	Maintenance Therapy — 167
12.5.3	Around Time of Delivery — 168
12.6	Investigation for Thrombophilia — 169
12.7	Conclusions — 169
	References — 170

Shaun Yo, John Granton

13	Pulmonary Hypertension in Pregnancy — 173
13.1	Introduction — 173
13.2	Epidemiology of PAH — 174
13.3	The Risk of Pregnancy in Patients with PAH — 174
13.4	Physiological Effects of Pregnancy — 175
13.5	The Perils of PAH and Pregnancy — 176
13.6	General Principles and Supportive Therapy in Pregnancy — 177
13.7	PAH-Targeted Medications in Pregnancy — 178

- 13.8 Approach to PAH-targeted Treatment — **180**
- 13.9 Peripartum Management — **182**
- 13.10 Conclusions — **183**
References — **184**

Alina Blazer, Meyer Balter

- 14 Asthma in Pregnancy — 187**
 - 14.1 Introduction — **187**
 - 14.2 Changes in Respiratory Function During Pregnancy — **187**
 - 14.3 Effects of Pregnancy on Asthma — **187**
 - 14.3.1 Mechanisms for the Effect of Pregnancy on Maternal Asthma — **188**
 - 14.4 Effects of Asthma on Pregnancy: Maternal and Fetal Outcomes — **189**
 - 14.5 Treatment of Asthma in Pregnancy: General Principles — **190**
 - 14.6 Nonpharmacological Management — **190**
 - 14.7 Pharmacological Management — **191**
 - 14.7.1 Beta-Agonists — **191**
 - 14.7.2 Inhaled Corticosteroids — **192**
 - 14.7.3 Other Asthma Medications — **192**
 - 14.7.4 Health Behaviors — **193**
 - 14.8 Treatment of Acute Exacerbations — **193**
 - 14.9 Labor and Delivery — **194**
 - 14.10 Asthma Postpartum and Breastfeeding Implications — **195**
 - 14.11 Conclusion — **195**
References — **195**

Loïc Sentilhes, Hanane Bouchghoul, Aurélien Mattuizzi, Alizée Froeliger, Hugo Madar

- 15 Obstetric Hemorrhage — 199**
 - 15.1 Introduction — **199**
 - 15.2 Definitions and Thresholds for Intervention — **200**
 - 15.3 Incidence of Postpartum Hemorrhage (PPH) — **204**
 - 15.4 Causes of Postpartum Hemorrhage (PPH) — **204**
 - 15.5 Risk Factors for PPH — **204**
 - 15.6 Prevention of Postpartum Hemorrhage — **206**
 - 15.6.1 Active Management of the Third Stage of Labor — **206**
 - 15.6.2 Uterotonics — **206**
 - 15.6.3 Tranexamic Acid — **208**
 - 15.6.4 Other Prevention Techniques — **209**
 - 15.7 Treatment of Postpartum Hemorrhage — **209**
 - 15.7.1 First-Line Measures — **211**
 - 15.7.2 Second-Line Measures for Persisting Hemorrhage — **211**

- 15.7.3 Third-Line Measures for Refractory Hemorrhage — 217
- 15.8 After Postpartum Hemorrhage — 219
- 15.9 Conclusion — 219
- References — 220

Dongmei Sun, Nadine Shehata

- 16 Anemia in Pregnancy — 225**
 - 16.1 Introduction — 225
 - 16.2 Normal Hematological Physiological Changes — 225
 - 16.3 Iron Deficiency Anemia — 225
 - 16.3.1 Diagnosis — 226
 - 16.3.2 Management — 226
 - 16.4 Hemoglobin Disorders in General — 227
 - 16.5 Sick Cell Disease — 228
 - 16.5.1 Diagnosis — 228
 - 16.5.2 Fetal and Maternal Implications of Sick Cell Disease — 228
 - 16.5.3 Management — 229
 - 16.6 Thalassemia — 230
 - 16.6.1 Diagnosis — 230
 - 16.6.2 Fetal and Maternal Implications of Thalassemia — 231
 - 16.6.3 Management — 231
 - 16.7 Microangiopathic Hemolytic Anemia in General — 232
 - 16.8 Pregnancy-Associated Microangiopathic Hemolytic Anemia Syndromes — 232
 - 16.8.1 HELLP Syndrome — 232
 - 16.8.2 Thrombotic Microangiopathies Associated with MAHA — 233
 - 16.8.3 Thrombotic Thrombocytopenic Purpura — 234
 - 16.8.4 Complement-Mediated Thrombotic Microangiopathy — 234
 - 16.8.5 Management of TTP and HUS — 235
 - 16.8.6 Conclusions — 235
 - References — 236

Ann Kinga Malinowski, Emily Delpero

- 17 Sick Cell Disease in Pregnancy — 241**
 - 17.1 Introduction: Normal Hemoglobin — 241
 - 17.2 Sick Hemoglobin — 241
 - 17.3 Sick Cell Trait Versus Sick Cell Disease — 242
 - 17.4 Pathophysiology of Sick Cell Disease — 242
 - 17.5 Manifestations of Sick Cell Disease and Influence of Pregnancy — 243
 - 17.5.1 SCD-Related Pain — 243
 - 17.5.2 Chronic Anemia — 244

17.5.3	Cardiac Manifestations —	244
17.5.4	Pulmonary Manifestations —	245
17.5.4.1	Acute Chest Syndrome (ACS) —	245
17.5.4.2	Pulmonary Hypertension (PH) —	246
17.5.5	Splenic Manifestations —	247
17.5.6	Neurologic Manifestations —	247
17.5.7	Renal Manifestations —	247
17.5.8	Hepatic Manifestations —	248
17.6	Pregnancy Outcomes —	248
17.7	Preconception Care —	249
17.7.1	Fertility Preservation —	249
17.7.2	Determination of Fetal Risk —	249
17.7.3	Medical Optimization —	250
17.8	Antenatal Care —	250
17.8.1	Prenatal Diagnosis —	250
17.8.2	Fetal Surveillance —	251
17.8.3	Maternal Management —	251
17.8.3.1	General Approach —	251
17.8.3.2	Prevention of Preeclampsia —	251
17.8.3.3	Acute Pain Crisis —	252
17.8.3.4	Analgesia during VOE —	252
17.8.3.5	The Role of Transfusion —	253
17.8.3.6	Intrapartum Care —	254
17.8.3.7	Postpartum Care —	254
17.9	Newborn Considerations —	255
17.9.1	Genetic Testing —	255
17.9.2	Neonatal Abstinence Syndrome (NAS) —	255
17.10	Conclusion —	255
	References —	256

Kristin Harris, Mark Yudin

18	Human Immunodeficiency Virus and Pregnancy —	261
18.1	Introduction —	261
18.2	Epidemiology —	261
18.3	Prenatal Testing —	262
18.4	Maternal and Perinatal Outcomes —	263
18.4.1	Maternal Outcomes —	263
18.4.2	Fetal Outcomes —	263
18.5	Preconception Management —	264
18.5.1	Counseling —	264
18.5.2	Medications —	264
18.5.3	Conception and Fertility Treatment Considerations —	265

18.5.4	Immunizations/Infections — 266
18.6	Pregnancy Management: Antenatal Care — 266
18.6.1	Schedule of Care — 266
18.6.2	Antiretroviral Therapy — 268
18.6.3	Special Circumstance — 270
18.7	Intrapartum Care — 270
18.7.1	Mode of Delivery — 270
18.7.2	Antiretroviral Therapy — 270
18.7.3	Special Considerations — 271
18.8	Postpartum Care — 272
18.8.1	Antiretroviral Therapy — 272
18.8.2	Infant Feeding — 272
18.8.3	Infant Care — 273
18.9	Conclusion — 274
	References — 274

Moran Shapira, Yoav Yinon

19	Congenital Cytomegalovirus Infection — 281
19.1	Introduction — 281
19.2	Congenital CMV Infection — 281
19.3	Prenatal Diagnosis of Maternal CMV Infection — 282
19.4	Prenatal Diagnosis of Fetal CMV Infection — 283
19.5	Prognostic Markers of CMV Disease — 285
19.5.1	Fetal Imaging — 285
19.5.2	DNA Counts in Amniotic Fluid — 285
19.5.3	Fetal Blood Parameters — 286
19.6	Prevention and Treatment of Intrauterine CMV Infection — 286
19.6.1	Prevention of Transmission — 286
19.6.2	Treatment of Intrauterine Infection — 287
19.6.3	Antiviral Drugs — 287
19.7	Prevention of Maternal CMV Infection — 289
19.8	Screening for CMV — 289
19.9	Conclusion — 290
	References — 290

Valentine Faure Bardon, Yves Ville

20	Fetal Toxoplasmosis — 297
20.1	Introduction — 297
20.2	Maternal Infection — 297
20.3	Fetal Infection — 298
20.4	Prognostic Markers of Fetal Infection — 299
20.4.1	Timing of Maternal Primary Infection (MPI) — 299

20.4.2	Findings on Imaging —	300
20.5	Prognostic Value of Imaging Findings —	300
20.5.1	Neurodevelopmental —	300
20.5.2	Chorioretinitis —	301
20.5.3	Contribution of Fetal Head MRI —	301
20.6	Prenatal Treatment —	301
20.6.1	Drugs —	302
20.6.2	Prevention of Mother-to-Fetus Transmission —	302
20.6.3	Antiparasitic Therapy to Reduce Fetal Complications —	303
20.7	Neonates Born to women with Toxoplasmosis Infection —	303
20.8	Comparison of Various Approaches —	304
20.9	Conclusion —	308
	References —	308

Daniela N. Vasquez, Maria-Teresa Pérez

21	Sepsis in Pregnancy —	313
21.1	Introduction —	313
21.2	Risk Factors —	313
21.3	Diagnosis —	314
21.4	Sources of Sepsis in Pregnant and Postpartum Patients —	316
21.5	Microorganisms Responsible for Maternal Sepsis —	318
21.6	Management —	318
21.7	Delivery Considerations —	323
21.8	Outcomes: Maternal Morbidity and Mortality due to Sepsis —	324
21.9	Conclusion —	324
	References —	324

Mónica Centeno, Diogo Ayres-de-Campos

22	Thyroid Disease in Pregnancy —	329
22.1	Introduction —	329
22.2	Thyroid Physiology During Pregnancy —	329
22.2.1	Maternal Thyroid Gland —	329
22.2.2	Fetal Thyroid Gland —	330
22.3	Hypothyroidism —	331
22.3.1	Definition —	331
22.3.2	Incidence —	331
22.3.3	Etiology —	331
22.3.4	Clinical Manifestations —	331
22.3.5	Diagnosis —	332
22.3.5.1	Hypothyroidism Diagnosed in Pregnancy —	332
22.3.6	Complications —	332

22.3.7	Management — 334
22.4	Iodine Deficiency — 334
22.5	Hyperthyroidism — 335
22.5.1	Definition and Incidence — 335
22.5.2	Etiology — 335
22.5.3	Clinical Manifestations — 335
22.5.4	Diagnosis — 335
22.5.5	Complications — 336
22.5.6	Management — 336
22.5.7	Management of Fetal and Neonatal Effects — 337
22.6	Thyroid Nodules — 337
22.7	Thyroid Cancer — 337
	References — 338

Sawyer Huguet-Penner, Denice S. Feig

23	Preexisting Diabetes in Pregnancy — 343
23.1	Introduction — 343
23.2	Maternal Risks of Preexisting Diabetes in Pregnancy — 343
23.3	Neonatal Risks of Preexisting Diabetes in Pregnancy — 345
23.4	Management of Preexisting Diabetes in Pregnancy — 347
23.4.1	Preconception Management — 347
23.4.2	Pregnancy Management — 348
23.4.3	Antepartum and Intrapartum Monitoring and Management — 350
23.5	Conclusion — 351
	References — 351

Maya Ram, Yariv Yogev

24	Gestational Diabetes Mellitus — 357
24.1	Introduction — 357
24.2	Risk Factors for GDM — 357
24.3	Pathophysiology of GDM — 358
24.4	The Offspring Point of View — 363
24.5	Prevention of Long-Term Effects on the Offspring — 365
24.6	Screening and Diagnosis for GDM — 365
24.6.1	“Two-Step” Method for Screening — 367
24.6.2	“One-Step” Method for Screening — 368
24.6.3	Optimal Diagnostic Approach – Evidence-Based — 368
24.6.4	Early Pregnancy Testing — 369
24.6.5	Repeat Testing — 370
24.7	Non-pharmacologic Management — 370
24.7.1	Prevention of Gestational Diabetes — 370
24.7.2	Lifestyle Intervention — 370

24.7.3	Glucose Monitoring and Targets —	371
24.8	Pharmacological Treatment —	372
24.8.1	Insulin —	372
24.8.2	Oral Antidiabetic Medication —	372
24.8.2.1	Metformin —	373
24.8.2.2	Sulfonylureas —	373
24.9	Obstetric Considerations —	373
24.10	Postpartum Management and Long-Term Maternal Health —	374
	References —	375

Haitham Baghlaf, Cynthia Maxwell

25	Obesity and Pregnancy —	387
25.1	Introduction and Epidemiology —	387
25.2	Preconception —	388
25.3	First Trimester —	390
25.3.1	Maternal Considerations —	390
25.3.2	Fetal Considerations —	391
25.4	Second Trimester —	392
25.4.1	Maternal Considerations —	392
25.4.2	Fetal Considerations —	392
25.5	Third Trimester —	392
25.5.1	Maternal Considerations —	392
25.5.2	Fetal Considerations —	394
25.5.3	Intrapartum —	394
25.6	Postpartum —	396
25.7	Conclusion —	397
	References —	397

Vivian Huang, Geoffrey C. Nguyen

26	Managing Inflammatory Bowel Disease During Pregnancy —	405
26.1	Background —	405
26.2	Prepregnancy and Inflammatory Bowel Disease —	405
26.2.1	Voluntary Childlessness —	405
26.2.2	IBD Disease Activity —	405
26.2.2.1	IBD Medications —	406
26.2.2.2	IBD-Related Surgeries —	406
26.3	Pregnancy with Inflammatory Bowel Disease —	406
26.4	IBD Medications —	407
26.4.1	Sulfasalazine and 5-Aminosalicylates —	407
26.4.2	Immunomodulators —	408
26.4.3	Biologics —	408
26.4.4	Small Molecules —	409

- 26.4.5 Corticosteroids — 409
- 26.5 Delivery and Postpartum — 410
- 26.6 Conclusion — 410
- References — 411

Homero Flores-Mendoza, Harrison Banner, John W. Snelgrove

27 Intrahepatic Cholestasis of Pregnancy — 413

- 27.1 Introduction — 413
- 27.2 Etiology — 413
 - 27.2.1 Genetics — 413
 - 27.2.2 Hormonal — 414
 - 27.2.3 Environmental — 414
 - 27.2.4 History of Prior Liver Disease — 414
- 27.3 Clinical Manifestations — 415
- 27.4 Diagnosis — 415
- 27.5 Maternal and Fetal Implications — 418
- 27.6 Treatment — 418
- 27.7 Delivery — 419
- References — 420

Ghaydaa Aldabie, Karen A. Spitzer, Carl A. Laskin

28 Pregnancy and the Rheumatic Diseases — 423

- 28.1 Introduction — 423
- 28.2 Rheumatoid Arthritis — 423
 - 28.2.1 Effects of RA on Pregnancy — 423
 - 28.2.2 Effects of Pregnancy on RA — 424
- 28.3 Management of Rheumatoid Arthritis During Pregnancy — 424
 - 28.3.1 Nonsteroidal Anti-inflammatory Drugs — 424
 - 28.3.2 Glucocorticoids — 425
 - 28.3.3 Conventional Disease-Modifying Antirheumatic Drugs — 425
 - 28.3.4 Methotrexate — 426
 - 28.3.5 Leflunomide — 426
 - 28.3.6 Sulfasalazine — 427
 - 28.3.7 Tumor Necrosis Factor Inhibitors (anti-TNF) — 427
 - 28.3.8 Injectable Anti-TNF Agents — 427
 - 28.3.9 Janus Kinase Pathway Inhibitors — 427
- 28.4 Systemic Lupus Erythematosus — 428
 - 28.4.1 Prepregnancy Assessment — 428
 - 28.4.2 Disease Activity — 428
 - 28.4.3 Medication Review — 429
 - 28.4.4 Assessment of Autoantibodies — 429
- 28.5 The Effects of Pregnancy on SLE — 429

28.5.1	SLE Flare —	429
28.5.2	Renal Disease —	430
28.5.3	Preeclampsia —	430
28.5.4	The Effects of SLE on Pregnancy —	431
28.5.5	Neonatal Lupus —	431
28.5.6	Antiphospholipid Antibodies and Pregnancy —	432
28.5.7	Advise Against Pregnancy/Early Therapeutic Termination —	432
28.5.8	Contraception —	433
28.6	Specific Medication Use in the Management of SLE During Pregnancy —	433
28.6.1	Antimalarials —	433
28.6.2	Azathioprine —	434
28.6.3	Mycophenolate Mofetil —	434
28.6.4	Cyclophosphamide —	435
28.7	Conclusion —	435
	References —	436

Tadeu A. Fantaneanu, Esther Bui

29	Epilepsy and Pregnancy —	441
29.1	Introduction —	441
29.2	Preconception —	441
29.2.1	Contraception —	441
29.2.2	Preconception Risk Stratification —	443
29.2.3	Folate Supplementation —	445
29.3	Pregnancy —	446
29.3.1	Therapeutic Drug Monitoring —	446
29.3.2	Vitamin K Administration —	446
29.3.3	Seizures and Emergencies in Pregnancy —	447
29.3.4	Labor and Delivery —	447
29.4	Postpartum —	448
29.4.1	Breastfeeding —	448
29.4.2	Safety in the Postpartum period —	449
29.5	Conclusion —	449
	References —	450

Arieh Ingber

30	Specific Dermatoses of Pregnancy —	453
30.1	Introduction —	453
30.2	Polymorphic Eruption of Pregnancy (PEP) —	453
30.2.1	Epidemiology —	453
30.2.2	Pathogenesis —	453

30.2.3	Clinical Presentation —	454
30.2.4	Laboratory Tests —	454
30.2.5	Histopathology —	454
30.2.6	Treatment —	455
30.2.7	Prognosis —	455
30.3	Pemphigoid Gestationis (PG) —	455
30.3.1	Epidemiology —	455
30.3.2	Pathogenesis —	456
30.3.3	Clinical Presentation —	456
30.3.4	Laboratory Tests —	456
30.3.5	Histopathology and Immunofluorescence —	457
30.3.6	Treatment —	457
30.3.7	Prognosis —	457
30.4	Impetigo Herpetiformis, also Known as Generalized Pustular Psoriasis of Pregnancy —	458
30.4.1	Nomenclature —	458
30.4.2	Epidemiology —	458
30.4.3	Pathogenesis —	458
30.4.4	Clinical Presentation —	459
30.4.5	Laboratory Investigations —	459
30.4.6	Histopathology —	459
30.4.7	Treatment —	459
30.4.8	Prognosis —	460
30.5	Prurigo of Pregnancy (Besnier) —	460
30.5.1	Epidemiology —	460
30.5.2	Clinical Presentation —	460
30.5.3	Laboratory Investigations —	461
30.5.4	Histopathology —	461
30.5.5	Treatment —	461
30.5.6	Prognosis —	461
30.6	Pruritic Folliculitis of Pregnancy —	461
30.6.1	Epidemiology —	461
30.6.2	Pathogenesis —	462
30.6.3	Clinical Presentation —	462
30.6.4	Laboratory Tests and Histopathology —	462
30.6.5	Treatment —	462
30.6.6	Prognosis —	462
30.7	Linear IgM Dermatitis of Pregnancy —	463
30.7.1	Pathogenesis —	463
30.7.2	Clinical Presentation —	463
30.7.3	Laboratory Tests —	463

- 30.7.4 Histopathology — **464**
- 30.7.5 Treatment — **464**
- 30.7.6 Prognosis — **464**
- References — **464**

Christoph Wohlmuth, Taymaa May

- 31 Gynecologic Cancer in Pregnancy — 469**
- 31.1 Introduction — **469**
- 31.2 Diagnosis — **469**
- 31.3 Surgery — **471**
- 31.4 Systemic Treatment — **473**
- 31.4.1 Chemotherapy in Pregnancy — **473**
- 31.4.2 Endocrine Therapy — **477**
- 31.4.3 Targeted Therapies and Biologic Agents — **477**
- 31.5 Radiation Therapy — **477**
- 31.6 Obstetric Management — **477**
- 31.7 Conclusion — **478**
- References — **478**

Evangelia Vlachodimitropoulou Koumoutsea, Cynthia Maxwell

- 32 Maternal and Fetal Malignancies in Pregnancy — 483**
- 32.1 Epidemiology — **483**
- 32.2 Diagnosing Cancer in Pregnancy — **483**
- 32.2.1 Imaging — **484**
- 32.2.2 Laboratory Markers — **484**
- 32.3 Specific Cancers in Pregnancy — **484**
- 32.3.1 Breast Cancer — **484**
- 32.3.2 Lymphoma and Leukemia — **485**
- 32.3.3 Melanoma — **486**
- 32.4 Targeted Therapies for Certain Malignancies in Pregnancy — **487**
- 32.4.1 Tamoxifen — **487**
- 32.4.2 Human Epidermal Growth Factor Receptor 2 (HER2) — **488**
- 32.4.3 Tyrosine Kinase Inhibitors — **488**
- 32.4.4 All-Trans Retinoid Acid (ATRA) — **489**
- 32.4.5 CAR T-Cell Therapy — **489**
- 32.5 Fetal Tumors — **490**
- 32.5.1 Sacrococcygeal Teratomas — **490**
- 32.5.2 Neck Teratomas — **490**
- 32.6 Counseling for This and Future Pregnancy — **491**

32.7	Conclusion —	492
	References —	493

Index —	497
---------	-----